해당없음상태 미확인
An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years
연구 개요
The goal of this bridging study is to assess the safety and immunogenicity of BARYCELA inj. in healthy Vietnamese children aged between 12 months to 12 years. The main questions it aims to answer are: * Safety of BARYCELA inj. (Live attenuated varicella vaccine for injection) * Immunogenicity of BARYCELA inj. (Live attenuated varicella vaccine for injection) Participants will be administered subcutaneously with a single dose(0.5 mL dose) of the BARYCELA inj.(MG1111) on the upper arm (brachia lateral).
- 스폰서
- 리드: GC녹십자
- 적응증
- Varicella Zoster Virus Infection
- 중재
- MG1111
- 목표 등록
- 250명
- 시작일
- 2023-02-01
- 완료(예정)
- 2023-06-01
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.